Neuronascent, a Maryland-based company, specializes in discovering and developing first-in-class, small-molecule therapeutics that target depression, neurodegenerative diseases (such as Alzheimer's and Parkinson's), and Down syndrome. Their neuron regeneration platform offers potential treatment options for reversing neurological disorders. Through a novel screening process, Neuronascent has identified small molecule candidates that stimulate the growth of new neurons in the brain and ensure their survival under neurodegenerative conditions. These candidates have shown promising results in both human neuronal progenitors and animal models of chronic neurological diseases. With a strong track record of meeting drug-development milestones, Neuronascent aims to provide disease-modifying therapeutic options for millions of patients suffering from chronic neurodegenerative disorders.